Safety of Intracameral Moxifloxacin and Dexamethasone in Phacoemulsification: 3-Year Results
Purpose
Determine safety of a combination of moxifloxacine + dexametazone used intracemeraly in phacoemulsification.
Methods
Two groups are included. inclusion criteria: no other ocular or systemic pathology but cataract. complete preop and postop evaluations included specular microscopy, biomicroscopy and macular OCT. In 24 eyes intracameral moxifloxacion + dexametazone was used and 24 using BSS at the end of phaco. Patients were seen postop days 1, 7, 30-43, and 3, 6, 12, 24, 36 months. Comparison of clinical findings between the 2 groups were analyzed.
Results
Twenty-eight patients completed the 3 year deadline. Ocular inflammation (hogan classification) was less at 1 day postop, and were the same at the 7th day. There were not statistical differences after one week postop in specular microscopy, biomicroscopy,\and macular OCT.
Conclusion
The combination of intracameral moxifloxacin+dexametazone in phacoemulsification is safe for ocular structures.